Effects of dietary protein quantity during weight reduction on changes in lean body mass, resting energy expenditure and physical function in obese postmenopausal women - a randomized controll trail

Effects of dietary protein quantity during weight reduction on changes in lean body mass, resting energy expenditure and physical function in obese postmenopausal women - a randomized controll trail - ProSeni

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00011238

Enrollment

Registered

2017-03-09

Start date

2017-01-26

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight

Interventions

Group 1: Participants will receive a hypocaloric diet (-750 kcal of total energy expenditure) with protein intake on RDA recommendations of 0.8 g/kg body weight daily for 12 weeks. Group 2: Participa

Eligibility

Sex/Gender

Female

Age

50 Years to 85 Years

Inclusion criteria

Inclusion criteria: - healthy postmenopausal women - aged 50 and older - obesity (BMI =30 m²/kg or =27 m²/kg and waist circumference of >88 cm) - ability to understand the study protocol und to ask if they have questions - ablility to walk without auxiliaries, to step ten stairs and to presume their typical daily activities - consistant physical activity since the las three months -

Exclusion criteria

Exclusion criteria: - weight change ± five percent in the last six months - BMI >35 kg/m² (because of bioelectrical impedance analysis method) - type 2 diabetes - creatinine >2,0 mg/dl - thyroid disease - medication (steroids, diuretics, thyroid drugs, statins, weight loss medication, insulin, beta blockers) - life expectancy under two years - participation in other weight loss programs - kidney or liver failure - anemia - chronic inflammation - protein supplementation during the last three months - high physical activity level (PAL >2) - heart diseases - neurological disorders- - electronic implants - active prostheses - life-sustaining electronic devices - portable electronic medical devices - aversion or allergy to whey products - inability to give complete written forms and consent - unwillingness to be randomized in one of the two intervention groups and to follow the study protocol for 12 weeks.

Design outcomes

Primary

Measure	Time frame
Fat free mass using bioelectrical impedance analysis (seca mBCA 515/514) baseline and after the intervention time of 12 weeks	—

Secondary

Measure	Time frame
resting energy expenditure using indirect calorimetry, physical functioning (Handgrip strength by jamar-dynamometer, balance and power by short physical performance battery) baseline and after the intervention time of 12 weeks	—

Countries

Germany

Contacts

Public ContactIsabell Englert

Hochschule Fulda

isabell.englert@oe.hs-fulda.de066196403481

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026